AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing
Avacta Group PLC (AVCT.L) AffiDX Receives CE Mark for Consumer Self-Testing
Hemogenyx Pharma Plc (HEMO.L) Hemo-CAR-T partnership with WuXi ATU
Partnership with WuXi Advanced Therapies to manufacture lentiviral vectors for phase I trial of cutting edge HEMO-CAR-T programme
Avacta Group PLC (AVCT.L) AffiDx® lateral flow test detects Omicron variant
Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is pleased to announce that
Hemogenyx Pharma Plc (HEMO.L) HEMO-CAR-T pre-IND Meeting Request
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases.
Avacta Group PLC (AVCT.L) FDA Approval of IND Application for AVA6000
Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000
Avacta Group PLC (AVCT.L) Update on UK Availability of AffiDX Test
Update on UK Availability of AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test following Implementation of CTDA Regulations
The highs and lows of drug launches
Every drug has its beneficiaries, whether they are suffering from a common chronic disease, a more severe form of cancer or a rare condition that affects 1 in 10,000 people. However,
Hemogenyx Pharma Plc (HEMO.L) Lease of New York Mink Building Custom Laboratory
Hemogenyx Pharmaceuticals has signed a lease with The Janus Property Company (“Janus”) for a new custom-designed and built laboratory in the Mink Building, located in the Manhattanville Factory District of
Hemogenyx Pharma Plc (HEMO.L) CDX Licence Agreement
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the “Agreement”) with the global biopharmaceutical
Oxford Nanopore valued at £4.93bn as shares soar in London debut
Investors snapped up shares in biotech company Oxford Nanopore after its IPO this morning, with the shares soaring 45 per cent.
Avacta Group PLC (AVCT.L) New appointments to Scientific Advisory Board
Avacta announces new appointments to the Scientific Advisory Board of its Therapeutics Division
